Shareholder Meeting Quorum Troubles
Nicox Appoints Ad Hoc Representative for June 2026 Shareholder Meeting Due to Quorum Difficulties
Anonymous
Nicox SA, a French ophthalmology company listed on Euronext Growth Paris, has scheduled its Ordinary and Extraordinary General Meeting for June 24, 2026 at 2:30 p.m. at its Sophia Antipolis headquarters. To guarantee the meeting can proceed, a court-appointed representative has been named to vote on behalf of shareholders who do not participate, GlobeNewswire reported.
This is the third straight year Nicox has used the tactic. The move reflects a broader governance challenge: 94.15% of the company's 93.5 million shares are held by retail investors, making it nearly impossible to hit the quorum required by French law, according to Yahoo Finance.
Court-Appointed Representative Guarantees 100% Quorum
On May 12, 2026, the President of the Antibes Commercial Court appointed Maître Thibault Ezavin as the ad hoc representative. An ad hoc representative is a neutral third party who votes the shares of people who stay silent. This effectively brings participation to 100%, ensuring resolutions can be voted on, Market Screener reported.
The voting formula is fixed by court order. For ordinary resolutions, the representative splits votes 50% for and 50% against. For extraordinary resolutions approved by the board, it is two-thirds for and one-third against. For extraordinary resolutions the board does not support, it flips — one-third for and two-thirds against. Board-backed proposals are nearly certain to pass.
Nicox's Financial Turnaround Sets Stage for 2026 Votes
The June 24 meeting arrives as Nicox posts its strongest financials in years. The company reported €16.8 million in revenue for 2025, up from €7.9 million in 2024. Its net loss shrank to €2.4 million — a 90% improvement from the €22.4 million loss the year before, according to Yahoo Finance.
CEO Gavin Spencer called 2025 "a pivotal turning point" and said the company's focus for 2026 is "supporting the submissions of the NCX 470 New Drug Applications." Nicox also fully repaid its Kreos Capital debt in January 2026, extending its cash runway into 2027. The company is targeting a $7 billion global glaucoma market with its lead drug, NCX 470.
Share Warrants and Capital Powers Hang on Meeting Outcome
The meeting's agenda includes renewing the board's authority to raise capital. With the ad hoc representative in place, those authorizations are expected to pass easily. Nicox also has 10 million warrants expiring on June 19, 2026 — five days before the meeting — priced at €0.275 per share. If exercised, they could bring in millions of euros in fresh cash, ADVFN noted.
Analyst Yi Chen at H.C. Wainwright keeps a "Buy" rating on the stock. He argues that paying off secured debt and receiving milestone payments from Japanese partner Kowa have reduced risk ahead of the FDA filing. The stock has traded near €0.38 on Euronext Growth Paris. Retail investors on French forums are watching the warrant deadline as a key share price signal.
Critics Warn Mechanism Drowns Out Active Minority Votes
The ad hoc approach has its critics. Governance advocates argue the system hurts shareholders who actually show up to vote against dilutive measures. Their "No" votes get overwhelmed by the representative's automatic two-thirds "Yes" on board-backed proposals. French corporate law experts describe the tool as practical for penny stocks with wide retail bases, but note it tilts outcomes toward management, according to Market Screener.
Nicox frames the mechanism differently. Management calls it a cost-saving measure that avoids the expense of a second meeting. From a trading standpoint, Euronext Growth investors largely treat the June 24 meeting as a non-event. Market attention stays fixed on the NCX 470 NDA submission expected in summer 2026. Meeting documents and proxy forms are available on the Nicox company website.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
5
Articles
5
Reach
5
A
AnonymousAuthor
